MR

Mark Ralph

President and Chief Executive Officer at Axine Water Technologies

Bethel, Connecticut

Invests in

Stages:

  • Min Investment:

    $3,250,000.00
  • Max Investment:

    $17,000,000.00
  • Target Investment:

    $8,500,000.00

Work Experience

  • President and Chief Executive Officer

    2022

2021 - 2022

  • Member Board Of Directors

    2021 - 2022

2021 - 2022

  • Member Board Of Directors

    2021 - 2022

2021 - 2022

  • Member Board Of Directors

    2021 - 2022

2001 - 2022

  • Executive Director, Boehringer Ingelheim Venture Fund

    2020 - 2022

    Lead investment prospecting efforts focused on digital health and therapeutics. Solicited input from subject matter experts, legal and finance colleagues to conduct cross-functional product research, financial analysis, due diligence, and scientific evaluation of potential investments. Develop negotiation terms and facilitate all negotiations. Own all decision-making for executed investor documents. Serve as board member or observer for portfolio companies.

  • Global Head of Contracts and Alliance Management, US Head of Business Development/Licensing

    2019 - 2020

    Provided leadership to 17-person team comprising contracts and alliance management (CAM) group as well as US-based business development and licensing (BDL) professionals. Led all operations and administration of BDL group, including personnel management, compliance, and contract execution. Oversaw administration of drug discovery collaborations across biotech, academic, and pharmaceutical partners, engaging directly with collaborators as needed. Hosted visibility events across US, including office hours and partner events; participated in multiple panel discussions and facilitated CEO roundtable educating early-stage CEOs on best practices for engaging with pharmaceutical companies and venture investors.

  • Executive Director, Global Head, Contracts and Alliance Management, BD&L

    2016 - 2019

    Spearheaded development and execution of framework to operationalize CAM division, including creation and introduction of new processes and procedures. Grew CAM team from 3 to 11 employees and traveled routinely to engage and collaborate with distributed staff across Austria, Germany, and US. Oversaw administration of drug discovery partnerships across biotech, academic, and pharmaceutical companies, engaging directly with partners as needed. Served as global head of Research Beyond Borders strategic partnering, leading identification, evaluation, negotiation, and management of all collaborations in areas outside of Boehringer Ingelheim’s core therapeutic areas. Responsible for the planning and monitoring of external collaboration and licensing budget exceeding $250M.

  • Director, External Partnerships and Financial Strategy

    2014 - 2016

    Facilitated access to new technologies in support of research, and development (R&D) efforts. Served as business liaison to R&D team and led scouting and due diligence for new partnership opportunities. Collaborated with internal stakeholders, including legal and strategic sourcing, to lead contract negotiations with academic and biotech groups. Managed allocation and spending of annual external resource budget of up to $30M.

  • Senior Associate Director, External Research Operations

    2010 - 2014

    Led scouting and evaluation efforts for new technologies and outsourcing partnerships that aided in the advancement of Boehringer Ingelheim's drug discovery efforts. Collaborated with cross-functional teams to influence new policies and procedures supporting standardized interactions with healthcare providers, ensuring compliance with government regulations including physician payments covered under the Sunshine Act. Participated in exclusive leadership development program optimizing potential of high-performing leaders. Gained comprehensive negotiation knowledge and techniques by completing immersive negotiation course including multiple situational simulations and live performance feedback. Received 2013 Presidents Award to recognize contributions to launch of standardized healthcare provider engagement procedures.

  • Finance Manager, Prescription Medicine Controlling

    2010 - 2010

    Collaborated with prescription medicine brand teams to appropriately construct and maintain direct promotion budgets exceeding $100M annually.

  • Department Logistics Manager, Medicinal Chemistry

    2006 - 2010

    Directed day-to-day operations for 38 contracted scientists in China and India performing chemical synthesis. Led cross-functional global committee to standardize processes and drive productivity. Managed budget and operational activity for 150-person team, ensuring support for staff of scientists. Implemented internally developed technology solutions that optimized ordering and stocking of chemicals and supplies.

  • Scientist, Medicinal Chemistry

    2001 - 2006

    Independently analyzed structure-activity relationships and devised probable synthetic routes of therapeutic agents in discovery and development for treatment of inflammatory disorders.